Bottom line
BBH vs PBE: the short answer
BBH (VanEck Biotech ETF) and PBE (Invesco Biotechnology & Genome ETF) share a meaningful slice of their top holdings — about 40% by weight.
BBH is cheaper at 0.35% vs 0.59% — a difference of $24 a year per $10,000 invested.
Over five years, PBE returned +3.4% a year vs +2.7% for BBH.
Updated Nov 19, 2026
BBH vs PBE side by side
| BBH | PBE | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | VanEck | Invesco |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.35% | 0.59% |
| Annual cost per $10k | $35 | $59 |
| 10-yr cost on $10k (prospectus) | $443 | $738 |
| Max front load | None | None |
| 12b-1 fee | — | — |
| 1-yr return | +21.2% | +24.7% |
| 5-yr return (annualized) | +2.7% | +3.4% |
| 10-yr return (annualized) | +4.5% | +5.2% |
| Best quarter | +27.6% | +25.3% |
| Worst quarter | −18.2% | −24.3% |
| Net assets (fund) | $395.6M | $281.9M |
| Number of holdings | 25 | 33 |
| Portfolio turnover | 19% | 103% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | BBH | PBE | Difference |
|---|---|---|---|
| 2025 | +21.2% | +24.7% | −3.5% |
| 2024 | −4.4% | +1.1% | −5.5% |
| 2023 | +3.9% | +3.7% | +0.2% |
| 2022 | −15.1% | −10.8% | −4.3% |
| 2021 | +11.8% | +1.6% | +10.2% |
| 2020 | +22.1% | +25.5% | −3.5% |
| 2019 | +25.8% | +18.3% | +7.5% |
| 2018 | −10.2% | +0.2% | −10.5% |
| 2017 | +16.6% | +22.4% | −5.8% |
| 2016 | −15.0% | −23.0% | +8.0% |
Source: Fund prospectus bar charts
Holdings overlap
12 of BBH's top 25 holdings also appear in PBE's top 25.
| Holding | BBH | PBE |
|---|---|---|
| Amgen Inc | 15.25% | 5.22% |
| Gilead Sciences Inc | 12.79% | 4.43% |
| Vertex Pharmaceuticals Inc | 9.10% | 4.99% |
| Regeneron Pharmaceuticals Inc | 6.21% | 5.47% |
| Alnylam Pharmaceuticals Inc | 3.83% | 3.17% |
| Biogen Inc | 3.63% | 4.79% |
| Illumina Inc | 3.17% | 3.51% |
| United Therapeutics Corp | 2.83% | 4.08% |
| Incyte Corp | 2.49% | 3.06% |
| Neurocrine Biosciences Inc | 2.08% | 2.66% |
| Bio-Techne Corp | 1.54% | 3.73% |
| BioMarin Pharmaceutical Inc | 1.34% | 2.82% |
Source: SEC Form N-PORT
BBH top 10
- Amgen Inc — 15.25%
- Gilead Sciences Inc — 12.79%
- Vertex Pharmaceuticals Inc — 9.10%
- Regeneron Pharmaceuticals Inc — 6.21%
- Revolution Medicines Inc — 5.27%
- Argenx SE — 4.97%
- Natera Inc — 4.92%
- IQVIA Holdings Inc — 4.31%
- Alnylam Pharmaceuticals Inc — 3.83%
- Biogen Inc — 3.63%
PBE top 10
- Invesco Private Prime Fund — 12.89%
- Regeneron Pharmaceuticals, Inc. — 5.47%
- Amgen Inc. — 5.22%
- CareDx, Inc. — 5.04%
- Vertex Pharmaceuticals Inc. — 4.99%
- Invesco Private Government Fund — 4.97%
- Royalty Pharma PLC — 4.94%
- Biogen Inc. — 4.79%
- Gilead Sciences, Inc. — 4.43%
- United Therapeutics Corp. — 4.08%
FAQ
What is the difference between BBH and PBE?
Which is cheaper, BBH or PBE?
Should I own both BBH and PBE?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.